Publication

The SPP biotech module 1: proteins for medical applications: a multidisciplinary effort for the development of a recombinant anti-RhD antibody preparation for the prevention of hemolytic disease of the newborn

Urs von Stockar, Lucia Baldi Unser, Patrick Pugeaud
1999
Conference Papers

Abstract

A review with 0 refs. is presented regarding studies of a multidisciplinary team to establish the prophylactic principle and the manufg. process for anti-Rh D therapy based on recombinant antibody prepns. produced from Chinese hamster ovary cells. [on SciFinder (R)]

Official source

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Urs von Stockar, Lucia Baldi Unser, Patrick Pugeaud
1999
Conference Papers

Abstract

Official source

Related concepts (16)

Hemolytic disease of the newborn

Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis foetalis, is an alloimmune condition that develops in a fetus at or around birth, when the IgG molecules (one of the five main types of antibodies) produced by the mother pass through the placenta. Among these antibodies are some which attack antigens on the red blood cells in the fetal circulation, breaking down and destroying the cells. The fetus can develop reticulocytosis and anemia.

Rho(D) immune globulin

Rho(D) immune globulin (RhIG) is a medication used to prevent RhD isoimmunization in mothers who are RhD negative and to treat idiopathic thrombocytopenic purpura (ITP) in people who are Rh positive. It is often given both during and following pregnancy. It may also be used when RhD-negative people are given RhD-positive blood. It is given by injection into muscle or a vein. A single dose lasts 12 weeks. It is made from human blood plasma. Common side effects include fever, headache, pain at the site of injection, and red blood cell breakdown.

Rh disease

Rh disease (also known as rhesus isoimmunization, Rh (D) disease, and blue baby disease) is a type of hemolytic disease of the fetus and newborn (HDFN). HDFN due to anti-D antibodies is the proper and currently used name for this disease as the Rh blood group system actually has more than 50 antigens and not only the D-antigen. The term "Rh Disease" is commonly used to refer to HDFN due to anti-D antibodies, and prior to the discovery of anti-Rho(D) immune globulin, it was the most common type of HDFN.

Related publications (1)

The SPP biotech module 1: proteins for medical applications: a multidisciplinary effort for the development of a recombinant anti-RhD antibody preparation for the prevention of hemolytic disease of the newborn

Chat with Graph Search

Biotechnology in Lausanne. The Rh D project